A Phase 2/3 interventional study of Semaglutide with 4 meal strategies and Placebo with 4 meal strategies in Type 1 Diabetes and Diabetes Mellitus, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2/3, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre — 7 open to participants now, 7 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · McGill University Health Centre/Research Institute of the McGill University Health Centre.
Among the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 2/3, and was the 12th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →7 of the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 2 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada, Switzerland
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6 · Phase 4 1
First in 2016; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 33 is below the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 34 across the 12 interventional studies, 380 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose levels. Primarily designed for managing type 1 diabetes, this system has demonstrated significant benefits in previous studies. Yet, despite these advantages, certain challenges persist.
Semaglutide, utilized in treating type 2 diabetes and obesity, is a once-weekly injectable medication that elevates levels of a gastrointestinal hormone known as Glucagon-Like Peptide-1 (GLP-1). This hormone alters gastric emptying, inhibits glucagon release, and reduces appetite. While not officially sanctioned for type 1 diabetes treatment in North America, studies have explored its efficacy as an adjunctive therapy alongside insulin, yielding favorable outcomes in blood glucose regulation. Comparable drugs like liraglutide and exenatide have been employed in type 1 diabetes treatment as well, albeit with less pronounced glucose-regulating effects compared to semaglutide, even in type 2 diabetes.
The goal of this 50-week randomized placebo-controlled crossover 2x4 factorial designed trial is to assess whether commercial automated insulin delivery (AID) systems using rapid-acting insulin with adjunct weekly injections of semaglutide (at the maximally tolerated dose) can replace carbohydrate counting with simple meal announcements (SMA) without degrading glucose control.
The main questions this study aims to answer are:
Can weekly injections of semaglutide at the maximum tolerated dose, in combination with ultra-rapid actin insulin (Lyumjev);
Participants will be asked to undergo two subsequent blinded drug interventions; one with semaglutide and the other with placebo. Both interventions include 4 meal strategies each with a 3-week duration; full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo with 4 meal strategies
Semaglutide is a Glucagon-like peptide 1 (GLP-1) receptor agonist. It up regulates GLP-1, which reduces glucagon levels, increases satiety and - in some particular cases - increases insulin production. It will be subcutaneously injected weekly by participants at progressively increasing doses. Once the maximum tolerated dose is achieved, participants will begin the meal strategies.
Drug: Semaglutide with 4 meal strategies
The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo)
Target range is defined to be between 3.9 and 10.0 mmol/L of plasma glucose for placebo vs semaglutide (at maximal tolerated dose) on closed-loop insulin therapy
Time frame: 24 weeks
Percentage of time spent in the range of glucose levels between 3.9 and 7.8 mmol/L
% as per CGM data
Time frame: 24 weeks
Percentage of time spent in glucose levels below 3.9 and 3.0 mmol/L
% as per CGM data
Time frame: 24 weeks
Percentage of time spent in glucose levels above 7.8, 10 and 13.9 mmol/L
% as per CGM data
Time frame: 24 weeks
Mean glucose level
Defined as per CGM data, in mmol/L
Time frame: 24 weeks
Standard deviation of glucose levels as a measure of glucose variability
Defined as per CGM data, in mmol/L
Time frame: 24 weeks
Percentage coefficient of variation of glucose levels
% as per CGM data
Time frame: 24 weeks
Proportions of participants with time in range between 3.9 - 10.0 mmol/L≥ 70%
As per CGM data
Time frame: 24 weeks
Glycated hemoglobin (HbA1c)
Blood test to assess glucose control within 3-4 months
Time frame: 24 weeks
Area under the curve 0-2h post meal, 0-3h post peal
As per CGM data
Time frame: 24 weeks
Average scores between interventions on the Type 1 Diabetes Distress Scale questionnaire
17-item questionnaire with a 6-point Likert scale from 1 (no stress) to 6 (high stress) for each item. Total score obtained from summing the scores of all items
Time frame: 24 weeks
Average scores between interventions on the Diabetes Treatment Satisfaction questionnaire
8-item questionnaire with a 7-point Likert scale ranging from 0 (low satisfaction) to 6 (high satisfaction). Total score obtained from summing the scores of all items.
Time frame: 24 weeks
Average scores between interventions based on the Hypoglycemic Fear Survey - II
33-item questionnaire with a 5-point Likert scale ranging from 1 (never) to 5 (almost always). Total score obtained from summing the scores of all items.
Time frame: 24 weeks
Heart rate
Beats per minute
Time frame: 24 weeks
Blood pressure
mmHg
Time frame: 24 weeks
Measure of body weight
Measurements done at visit - weight in kilograms
Time frame: 24 weeks
Measure of body mass index
Measurements done at visit - body mass index as per kg/m\^2
Time frame: 24 weeks
Measure of waist circumference and hip circumference
Measurements done at visit - circumference in cm
Time frame: 24 weeks
Measure of waist-to-hip ratio
Measurements done at visit
Time frame: 24 weeks
Lipid profile, specifically: LDL-cholesterol, HDL-cholesterol, triglycerides
Blood tests, in mmol/L
Time frame: 24 weeks
Urine albumin-creatinine ratio
Urine test
Time frame: 24 weeks
Plan to share: Yes — The raw data (that is, insulin delivery, glucose levels and individual participant data) and informed consent form will be shared by the corresponding author, for academic purposes, subject to a material transfer agreement and approval of the McGill University Health Center's Research Ethics Board. All data shared will be de-identified. Raw data will be shared for non-commercial use upon reasonable request and a material transfer agreement.
Supporting information: Informed consent form
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
Of 19 phase 2/3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 36 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jan 2027 → Dec 2027 and completion Jan 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
McGill University Health Centre/Research Institute of the McGill University Health Centre →